These infections may develop or become more severe if you receive CIMZIA.
CIMZIA COPAY CARD ACTIVATION SKIN
warm, red, or painful skin or sores on your body.think you have an infection or have symptoms of an infection such as:.Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with CIMZIA.īefore starting CIMZIA, tell your healthcare provider if you:.Your healthcare provider should test you for TB before starting CIMZIA.
Some of these serious infections have caused hospitalization and death. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker that can lower the ability of your immune system to fight infections.What is the most important information I should know about CIMZIA?ĬIMZIA may cause serious side effects, including: Important Safety Information you should know about CIMZIA ® (certolizumab pegol) You are encouraged to report negative side effects of prescription drugs to the FDA. Please consult your doctor if you have any questions about your condition or treatment. Some program and eligibility restrictions apply. Any CIMplicity program may be amended or canceled at any time without notice. The CIMplicity program is provided as a service of UCB, Inc., and is intended to support the appropriate use of CIMZIA.
CIMZIA COPAY CARD ACTIVATION FREE
Call ucbCARES ® toll free at 1-844-599-CARE (2273) for more information. ‡If you are uninsured, other financial assistance may be available. UCB reserves the right to rescind, revoke, or amend this Program without notice. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer. For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for CIMZIA by their commercial insurance plan. Program is not health insurance, nor is participation a guarantee of insurance coverage. Patients may be asked to reverify insurance coverage status during the course of the program.
Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program or where otherwise prohibited by law. †CIMplicity ® Covered™ Eligibility: Eligible patients with a valid prescription for CIMZIA can receive treatment with the CIMZIA Prefilled Syringe at no cost for up to two years or until the patient’s coverage is approved, whichever comes first. The parties reserve the right to amend or end this program at any time without notice. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. Product dispensed pursuant to program rules and federal and state laws. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. *CIMplicity Savings Program Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA.
0 kommentar(er)
